Serum p53 antibodies in patients affected with ulcerative colitis

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 606-611

  Cioffi, Michele ^a   Riegler, Gabrielle ^a   Vietri, Maria Teresa ^a   Pilla, Paola ^a   Caserta, Luigi ^a   Carratù, Romano ^a   Sica, Vicenzo ^a   Molinari, Maria ^a  

^a University School of Medicine Federico II   (Italy)

Author keywords

Anti p53 antibodies; Colorectal cancer; Ulcerative colitis

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL OBSERVATION; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SEROLOGY; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4644338038     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00016     Document Type: Article

References (43)

1. Gretarsdottir S, Tryggvadottir L, Jonasson GJ, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer. 1996;74:555-561.
2. Ridanpaa M, Karjalainen A, Anttila S, et al. Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol. 1994;5:1109-1117.
3. Soussi T. The p53 tumor suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today. 1996;32-37.
4. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today. 1996;17:354-356.
5. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777-1788.
6. El-Sayed ZA, Farag DH, Eissa S. Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pediatr Allergy Immunol. 2003;14:229-233.
7. Coomber D, Hawkins NJ, Clark M, et al. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol. 1996;122:757-762.
8. Ohshio G, Sawa H, Imamura M. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease. Int J Gastrointest Cancer. 2002; 31:129-135.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
10. Walsh S, Murphy M, Silverman M, et al. p27 expression in inflammatory bowel disease-associated neoplasia. Further evidence of a unique molecular pathogenesis. Am J Pathol. 1999;155:1511-1518.
11. Malcomson RD, Mc Gregor AH. Molecular screening for colon cancer in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1061-1066.
12. Yin J, Harpaz N, Tong Y, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1993;104:1633-1639.
13. Holzmann K, Klump B, Borchard F, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer. 1998;76:1-6.
14. Wong NACS, Harrison DJ. Colorectal neoplasia in ulcerative colitis. Histopathology. 2001;39:221-234.
15. Heinzlmann M, Lang SM, Neynaber S, et al. Screening for p53 and K-ras mutations in whole-gut lavage in chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1061-1066.
16. Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in non-cancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333-3337.
17. Lutz W, Nowakowska-Swirta E. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process. Int J Occup Med Environ Health. 2002;15:209-218.
18. Lashner BA, Shapiro BD, Husain A, et al. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1999;94:456-462.
19. Hardy RG, Meltzer SJ, Jankovski JA. ABC of colerectal cancer: molecular basis for risk factors. BMJ. 2000;321:886-889.
20. Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med. 2000;67:227-240.
21. Geboes K. Ulcerative colitis and malignancy. Acta Gastroenterol Belg. 2000;63:279-283.
22. Fujii S, Fujimori T, Chiba T. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res. 2003;22: 107-115.
23. Mudenda B, Green JA, Green B, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer. 1994;69:1115-1119.
24. Shapiro BD, Lashner BA. Cancer biology in ulcerative colitis and potential use in endoscopic surveillance. Gastrointest Endosc Clin N Am. 1997; 7:453-468.
25. Fricke H, Urban S, Noehl N, et al. Serum p53 antibodies in patients with chronic inflammatory bowel disease. Gut. 1998;42:899.
26. Powell-Tuck J, Day DW, Buckell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci. 1982;27:533-537.
27. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594-642.
28. Ridell RH, Goldman H, Ransohoff DF, et al. Goldman H, Ransohoff DF. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1988;14:931-968.
29. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations Crispin DA, Rabinovitch PS. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369-378.
30. Hammel P, Boissier B, Chaumette MT, et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut. 1997;40: 356-361.
31. Houbiers JGA, van der Burg SH, van der Watering LMG, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer. 1995;72:637-641.
32. Angelopoulou K, Stratis M, Diamandis EP. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer. 1997;70:46-51.
33. Shiota G, Ishida M, Noguchi N, et al. Circulating p53 in patients with colorectal cancer. Dig Dis Sci. 2000;45:122-128.
34. Hammel P, Leroy-Viard K, Chaumette MT, et al. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999;81:712-718.
35. Charuruks N, Tangkijvanich P, Voravud N, et al. Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. J Gastroenterol. 2001;36:830-836.
36. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1:701-702.
37. Portefaix JM, Fanutti C, Granier C, et al. Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods. 2002;259:65-75.
38. Sprung DJ, Lundeberg K. Do surveillance colonic biopsies in patients with ulcerative colitis prevent cancer in a community setting? Am J Gastroenterol. 2001;96:S309.
39. Bret A Lashner. Bradley D. Shapiro, Asif Husain, JR Goldblum. Evaluation of the usefulness for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol. 1999;94:456-462.
40. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994;107:934-944.
41. Shanahan F. Discontent with dysplasia surveillance in ulcerative colitis. Eur J Cancer. 1995;1:80-83.
42. Itzkowitz S. Colon cancerogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol. 2003;36: S70-S74.
43. Wild CP, Ridanpaa M, Anttila S, et al. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutations in the tumor tissue. Int J Cancer. 1995;64:176-181.